{"abstract":"The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). This meeting was announced in the Federal Register on June 30, 2026. The amendment is being made to reflect a change in the DATES, ADDRESSES, and SUPPLEMENTARY INFORMATION: Procedure portion of the document. There are no other changes.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/07/24/2026-15017.html","cfr_references":[],"citation":"91 FR 46788","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":null,"disposition_notes":null,"docket_ids":["Docket No. FDA-2026-N-7231"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2026-07-24","updated_at":"2026-07-24T10:57:54.676-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2026-N-7231-0129","allow_late_comments":false,"id":"FDA-2026-N-7231-0129","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2026-N-7231","title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec."}],"document_number":"2026-15017","effective_on":null,"end_page":46789,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/07/24/2026-15017.xml","html_url":"https://www.federalregister.gov/documents/2026/07/24/2026-15017/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-15017?publication_date=2026-07-24","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-07-24/2026-15017/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":203,"last_updated":"2026-09-23 02:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-24/pdf/2026-15017.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-15017.pdf?1784810713","publication_date":"2026-07-24","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/07/24/2026-15017.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2026-N-7231","supporting_documents_count":0,"docket_id":"FDA-2026-N-7231","document_id":"FDA-2026-N-7231-0129","regulation_id_number":null,"title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – Biologics License Application (BLA) 125827, from Replimune, Inc. for vusolimogene oderparepvec.","checked_regulationsdotgov_at":"2026-07-25T17:55:03Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":46788,"subtype":null,"title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec","toc_doc":"Cellular, Tissue, and Gene Therapies Advisory Committee; Biologics License Application 125827, from Replimune, Inc. for Vusolimogene Oderparepvec","toc_subject":"Hearings, Meetings, Proceedings, etc.","topics":[],"type":"Notice","volume":91}